Sarafan ChEM-H


Showing 11-16 of 16 Results

  • Michael R. Howitt

    Michael R. Howitt

    Assistant Professor of Pathology and of Microbiology and Immunology

    Current Research and Scholarly InterestsOur lab is broadly interested in how intestinal microbes shape our immune system to promote both health and disease. Recently we discovered that a type of intestinal epithelial cell, called tuft cells, act as sentinels stationed along the lining of the gut. Tuft cells respond to microbes, including parasites, to initiate type 2 immunity, remodel the epithelium, and alter gut physiology. Surprisingly, these changes to the intestine rely on the same chemosensory pathway found in oral taste cells. Currently, we aim to 1) elucidate the role of specific tuft cell receptors in microbial detection. 2) To understand how protozoa and bacteria within the microbiota impact host immunity. 3) Discover how tuft cells modulate surrounding cells and tissue.

  • KC Huang

    KC Huang

    Professor of Bioengineering and of Microbiology and Immunology

    Current Research and Scholarly InterestsHow do cells determine their shape and grow?
    How do molecules inside cells get to the right place at the right time?

    Our group tries to answer these questions using a systems biology approach, in which we integrate interacting networks of protein and lipids with the physical forces determined by the spatial geometry of the cell. We use theoretical and computational techniques to make predictions that we can verify experimentally using synthetic, chemical, or genetic perturbations.

  • Possu Huang

    Possu Huang

    Assistant Professor of Bioengineering

    Current Research and Scholarly InterestsProtein design: molecular engineering, method development and novel therapeutics

  • Adrian Hugenmatter

    Adrian Hugenmatter

    Director of Protein Engineering

    BioDr. Adrian Hugenmatter joined ChEM-H in 2021 and is leading the Protein Therapeutics Knowledge Center. Dr. Hugenmatter obtained his PhD in the laboratory of Prof. Donald Hilvert at the Swiss Federal Institute of Zurich (ETH Zurich), where he gained his first experience in enzymology, antibody engineering and directed evolution. Fascinated by protein engineering, he joined the laboratory of Prof. Dan Tawfik at the Weizmann Institute of Science (Israel), where he worked on molecular evolution. Dr. Hugenmatter then spent 11 years as a research scientist and team leader at Roche. During that time he developed and optimized several antibody lead candidates for therapeutic application in Oncology and Neuroscience. All along his career, Dr. Hugenmatter was and still is intrigued by the question how a ideal drug must look like to give the maximal benefit to the patient.

  • Paul S Humphries

    Paul S Humphries

    Alliance Director, Sarafan ChEM-H

    Current Role at StanfordAlliance Director, Stanford Innovative Medicines Accelerator (IMA)